177Lu-DOTA-0-Tyr3-octreotate infusion modeling for real-time detection and characterization of extravasation during PRRT.
Fiche publication
Date publication
mai 2022
Journal
EJNMMI physics
Auteurs
Membres identifiés du Cancéropôle Est :
Pr IMPERIALE Alessio, Dr POROT Clémence
Tous les auteurs :
Mazzara C, Salvadori J, Ritzenthaler F, Martin S, Porot C, Imperiale A
Lien Pubmed
Résumé
Given the recent and rapid development of peptide receptor radionuclide therapy (PRRT), increasing emphasis should be placed on the early identification and quantification of therapeutic radiopharmaceutical (thRPM) extravasation during intravenous administration. Herein, we provide an analytical model of Lu-DOTA0-Tyr3-octreotate (Lutathera) infusion for real-time detection and characterization of thRPM extravasation.
Mots clés
177Lu, Equivalent dose rate, Extravasation, Gravity infusion method, Lutathera, Neuroendocrine tumors, Peptide receptor radionuclide therapy, Radioprotection
Référence
EJNMMI Phys. 2022 May 3;9(1):33